Sign-up to Receive
Our Latest Insights

CURE
VanEck Genomics and Healthcare Innovators UCITS ETF

Fund Description

Technology is transforming healthcare. Not only are genomic treatments for several diseases becoming more affordable, but also digitalized healthcare is growing fast. VanEck’s Genomics and Healthcare Innovators UCITS ETF invests in the businesses pioneering ways to treat disease and connect with patients.

  • Invest in genomics companies developing new ways to treat health problems such as genetic conditions, cancer and conditions related to ageing
  • Gain exposure to digital health services providers – delivering easy access to doctors, physiotherapists, nurses and pharmacists
  • Pure-play exposure to companies earning at least half their revenues from genomics- or e-healthcare-related industries
  • Invest in an ETF that screens out companies that violate social norms, derive revenues from controversial weapons, or participate in fossil fuel sectors, nuclear power, civilian firearms or tobacco


Risk: You may lose money up to the total loss of your investment due to the Main Risk Factors such as Equity Market Risk and Industry Concentration Risk described below in the KID and in the sales prospectus. Evolving of the market not guaranteed.



Underlying Index

MVIS® Global Future Healthcare ESG Index (MVFHCTR)

Fund Details
 

  • Fund Ticker

    CURE

  • Management Company

    VanEck Asset Management B.V.

  • Custodian

    State Street Custodial Services (Ireland) Limited

  • Domicile

    Ireland

  • UCITS Compliant

    Yes

  • Index Ticker

    MVFHCTR

  • Index Provider

    MarketVector Indexes

  • Rebalance Frequency

    Semi-Annually
1The "Net Asset Value" (NAV) of all ETFs is determined at the close of each business day, and represents the value of one share of the fund; it is calculated by taking the total assets of the fund, subtracting total liabilities, and dividing by the total number of shares outstanding. The NAV is not necessarily the same as the ETF 's intraday trading value. Investors should not expect to buy or sell ETF shares at NAV.

2The date the fund was launched prior to quotation on the stock exchange.

 
as of 24 Mar 2023

  • NAV1

    21.04

  • Shares Outstanding

    310,000

  • Number of Holdings

    55

  • Base Currency

    USD

  • Net Assets

    $6.5M

  • Product Structure

    Physical (Full Replication)

  • Income Treatment

    Reinvestment

  • Distribution Frequency

    None

  • Total Expense Ratio

    0.35%

  • ISA Eligibility

    Yes

  • SIPP Available

    Yes

  • UK Reporting Status

    Yes

  • UK Distributor

    Yes

  • SFDR Classification

    Article 9
  • Fact Sheet
  • VanEck Product List
  • Fund Holiday Calendar

Trading Information as of 24 Mar 2023

Deutsche
Börse
EUR
Exchange Ticker CURE
ISIN IE000B9PQW54
SEDOL BNG7JX1
Bloomberg CURE GY
Reuters (RIC) CURE.DE
Valor 121031038
Bloomberg iNAV CUREUSIV
Reuters iNAV CUREINAV=SOLA
WKN A3DSGJ
Trading Currency EUR
Last Traded Price 19.46
Day's Move 0.09
Volume 749
30 Day Volume 181
VWAP Volume 749

NAVs as of 24 Mar 2023

Base
Currency 		NAV Daily
Change
NAV 		YTD
Change
NAV 		NAV Price
History 		Total
Expense
Ratio
CURE USD $21.04 $0.21 / +0.99% --
0.35

Performance History* (%)

View All ETFs View All Indices
  1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR ETF INCEPTION
MVFHCTR (Index) -7.48 -7.86 -3.83 -12.97 -- -- -- 0.18
  1 MO* 3 MO* YTD* 1 YR 3 YR 5 YR 10 YR ETF INCEPTION
MVFHCTR (Index) -4.19 8.94 -24.99 -24.99 -- -- -- 4.11
  2018 2019 2020 2021 2022
MVFHCTR (Index) -- -- -- -- -24.99

Past performance does not predict future returns.

ETF returns not available if there is less than one year’s performance data.

*Periods greater than one year are annualised.

Investing is subject to risk, including the possible loss of principal. You must read the Prospectus and

KIID

before investing, which are available at the Document section of the fund on www.vaneck.com.

ETF performance: Current performance may be lower or higher than average annual returns shown. Discrete performance shows 12-month performance for each of the last 10 years where available. E.g. '1st year' shows the most recent of these 12-month periods and '2nd year' shows the previous 12 month period and so on.

Performance data for the Irish domiciled ETFs is displayed on a Net Asset Value basis, in Base Currency terms, with net income reinvested, net of fees. Brokerage or transaction fees will apply.

Returns may increase or decrease as a result of currency fluctuations.

Index performance: Performance quoted represents past performance of the underlying Index. An index performance is not illustrative of the Product's performance. It is not possible to invest directly in an index: indices are not securities in which investments can be made.
For more information on the Index performance, please consult the Index Provider´s website.

MVIS® Global Future Healthcare ESG Index is the exclusive property of MarketVector Indexes GmbH (a wholly owned subsidiary of Van Eck Associates Corporation), which has contracted with Solactive AG to maintain and calculate the Index. Solactive AG uses its best efforts to ensure that the Index is calculated correctly. Irrespective of its obligations towards MarketVector Indexes GmbH (“MarketVector”), Solactive AG has no obligation to point out errors in the Index to third parties. The VanEck Genomics and Healthcare Innovators UCITS ETFis not sponsored, endorsed, sold or promoted by MarketVector and MarketVector makes no representation regarding the advisability of investing in the Fund.

Market Makers

Top 10 Holdings (%) as of 28 Feb 2023 View All Holdings »

Total Holdings: 55
Swipe<br>to view <br> full data
Holding Name
Ticker
 Shares Market Value
(USD) 		% of Net
Assets
VERTEX PHARMACEUTICALS INC VRTX US 1,720 499,299 7.97
REGENERON PHARMACEUTICALS INC REGN US 625 475,263 7.59
MODERNA INC MRNA US 3,052 423,648 6.76
DEXCOM INC DXCM US 3,765 417,953 6.67
ILLUMINA INC ILMN US 1,965 391,428 6.25
VEEVA SYSTEMS INC VEEV US 2,066 342,254 5.46
BIONTECH SE BNTX US 2,310 300,416 4.80
ALNYLAM PHARMACEUTICALS INC ALNY US 1,328 254,246 4.06
M3 INC 2413 JP 10,000 238,740 3.81
QIAGEN NV QGEN US 4,770 219,182 3.50
Top 10 Total (%) 56.87
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Country Weightings (%) as of 28 Feb 2023

  • Country

    % of Net Assets
  • ■

    United States

    80.02
  • ■

    China

    6.11
  • ■

    Germany

    5.60
  • ■

    Japan

    3.81
  • ■

    United Kingdom

    1.50
  • ■

    Switzerland

    1.25
  • ■

    Australia

    0.88
  • ■

    Sweden

    0.50
  • ■

    Netherlands

    0.31
  • ■

    Other/Cash

    0.04

Sector Weightings (%) as of 28 Feb 2023

  • Sector

    % of Net Assets
  • ■

    Health Care

    94.6
  • ■

    Consumer Discretionary

    4.9
  • ■

    Consumer Staples

    0.3
  • ■

    Materials

    0.2
  • ■

    Other/Cash

    0.0

Technology

Sustainable

Metal

Real Estate

Dividend

Discover more ETFs

More ETFs